Based on the SOLOIST-WHF (Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure) and SCORED (Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk) trials, there is now evidence to treat patients with heart failure with preserved ejection fraction with sodium-glucose cotransporter-2 (SGLT2) inhibitors and to start treatment early in heart failure with reduced ejection fraction and heart failure with preserved ejection fraction. In this interview, L. Kristin Newby, MD, MHS, FACC; Deepak L. Bhatt MD, FACC; and Shashank Sinha, MD, discuss the expanding biology of SGLT2.

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

Clinical Topics: Diabetes and Cardiometabolic Disease, Dyslipidemia, Heart Failure and Cardiomyopathies, Prevention, Lipid Metabolism, Acute Heart Failure

Keywords: ACCELLite, Heart Failure, Metabolic Syndrome, Primary Prevention, Sodium-Glucose Transporter 2, Diabetes Mellitus, Type 2, Stroke Volume, Cardiovascular Diseases, Risk Factors, Glycosides, Ventricular Dysfunction, Left, Renal Insufficiency

< Back to Listings